Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 6,000 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Rating) CEO Snehal Patel acquired 6,000 shares of Greenwich LifeSciences stock in a transaction that occurred on Tuesday, April 19th. The stock was purchased at an average cost of $16.74 per share, with a total value of $100,440.00. Following the completion of the purchase, the chief executive officer now owns 1,210,929 shares in the company, valued at approximately $20,270,951.46. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Snehal Patel also recently made the following trade(s):

  • On Thursday, April 21st, Snehal Patel acquired 6,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $16.09 per share, with a total value of $96,540.00.
  • On Friday, February 11th, Snehal Patel acquired 5,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $19.80 per share, with a total value of $108,900.00.
  • On Friday, February 4th, Snehal Patel bought 5,000 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $19.59 per share, with a total value of $97,950.00.

Shares of NASDAQ:GLSI opened at $15.91 on Friday. The business has a fifty day moving average of $19.51 and a two-hundred day moving average of $25.61. Greenwich LifeSciences, Inc. has a 52-week low of $15.52 and a 52-week high of $48.96.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its holdings in Greenwich LifeSciences by 106.4% in the 2nd quarter. Bank of America Corp DE now owns 770 shares of the company’s stock valued at $35,000 after buying an additional 397 shares during the period. Wells Fargo & Company MN increased its position in shares of Greenwich LifeSciences by 1,776.8% during the fourth quarter. Wells Fargo & Company MN now owns 2,346 shares of the company’s stock valued at $57,000 after acquiring an additional 2,221 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Greenwich LifeSciences by 9.9% in the 2nd quarter. Royal Bank of Canada now owns 3,076 shares of the company’s stock valued at $138,000 after acquiring an additional 276 shares during the period. UBS Group AG lifted its holdings in shares of Greenwich LifeSciences by 467.1% in the 3rd quarter. UBS Group AG now owns 4,310 shares of the company’s stock worth $168,000 after acquiring an additional 3,550 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Greenwich LifeSciences in the 4th quarter valued at approximately $107,000. Hedge funds and other institutional investors own 6.25% of the company’s stock.

Separately, Zacks Investment Research upgraded Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Thursday.

About Greenwich LifeSciences (Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery.

Read More

Insider Buying and Selling by Quarter for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.